|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.395 SEK | -0.36% |
|
+6.49% | -65.08% |
Scandion Oncology A/S reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was DKK 10.99 million compared to DKK 15.69 million a year ago. Basic loss per share from continuing operations was DKK 0.27 compared to DKK 0.39 a year ago.
Diluted loss per share from continuing operations was DKK 0.27 compared to DKK 0.39 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -65.08% | 5.27M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.44% | 21.25B | |
| -5.15% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +37.57% | 12.54B | |
| -26.24% | 8.09B |
SCANDION ONCOLOGY A/S 
